Hollow Brook Wealth Management LLC Has $4.14 Million Position in Standard BioTools Inc. (NASDAQ:LAB)

Hollow Brook Wealth Management LLC increased its position in Standard BioTools Inc. (NASDAQ:LAB) by 5.0% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 1,874,405 shares of the company’s stock after acquiring an additional 88,648 shares during the quarter. Standard BioTools accounts for 1.7% of Hollow Brook Wealth Management LLC’s holdings, making the stock its 18th largest position. Hollow Brook Wealth Management LLC’s holdings in Standard BioTools were worth $4,142,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Freedom Wealth Alliance LLC acquired a new stake in Standard BioTools during the 3rd quarter valued at approximately $59,000. Jump Financial LLC acquired a new stake in Standard BioTools during the 3rd quarter valued at approximately $94,000. Barclays PLC acquired a new stake in Standard BioTools during the 3rd quarter valued at approximately $140,000. Citigroup Inc. acquired a new stake in Standard BioTools during the 3rd quarter valued at approximately $550,000. Finally, Acadian Asset Management LLC acquired a new stake in Standard BioTools during the 3rd quarter valued at approximately $50,000. Institutional investors and hedge funds own 53.74% of the company’s stock.

Insider Buying and Selling

In other news, Director Casdin Partners Master Fund, L bought 250,000 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The shares were bought at an average cost of $2.57 per share, for a total transaction of $642,500.00. Following the acquisition, the director now directly owns 11,496,525 shares in the company, valued at $29,546,069.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 53.10% of the stock is owned by company insiders.

Standard BioTools Price Performance

Shares of Standard BioTools stock remained flat at $2.48 on Tuesday. The company’s stock had a trading volume of 2,748,734 shares, compared to its average volume of 2,249,573. The firm has a market cap of $719.50 million, a P/E ratio of -2.61 and a beta of 1.64. Standard BioTools Inc. has a 52-week low of $1.46 and a 52-week high of $3.16. The business has a 50 day moving average price of $2.61 and a 200-day moving average price of $2.34.

Standard BioTools (NASDAQ:LAB) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. The business had revenue of $28.19 million for the quarter, compared to the consensus estimate of $28.00 million. Sell-side analysts forecast that Standard BioTools Inc. will post -0.47 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LAB has been the subject of a number of recent analyst reports. TD Cowen assumed coverage on shares of Standard BioTools in a research report on Tuesday, April 16th. They set a “buy” rating and a $3.50 target price for the company. Jefferies Financial Group assumed coverage on Standard BioTools in a report on Thursday, April 4th. They set a “buy” rating and a $3.25 price target on the stock.

Standard BioTools Company Profile

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.